|

Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study

RECRUITINGSponsored by University Hospital Schleswig-Holstein
Actively Recruiting
SponsorUniversity Hospital Schleswig-Holstein
Started2021-06-01
Est. completion2027-12
Eligibility
Age50 Years – 99 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04724941

Summary

The PASS-PD study is set out to screen individuals from the general population with an increased risk for the development of Parkinson's Disease (PD) and to investigate this highly enriched cohort longitudinally for five year. A special focus is placed on implementation of ethical standards for early risk disclosure in PD.

Eligibility

Age: 50 Years – 99 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age between 50 and 99

Exclusion Criteria:

* Presence of clinical PD at the time of study inclusion
* Other significant neurologic diseases affecting the central nervous system (e.g. Multiple sclerosis)
* other significant diseases e.g. orthopaedic diseases affecting quantitative motor assessment
* in case of participation in the lumbal puncture substudy: contraindications for the performance of lumbal puncture (bleeding tendency, intake of anticoagulants)

Conditions2

Parkinson DiseaseParkinson's Disease

Browse More Trials

Parkinson's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.